lebrikizumab vs REGN20423
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-13 · full Atopic Dermatitis pipeline
lebrikizumab · Ebglyss
Marketed by Eli Lilly and partners
NCT04146363 · Phase 3 · completed
The randomized, quadruple-masked, placebo-controlled trial enrolled 424 participants and evaluated clinical skin outcomes as its two primary endpoints. At Week 16, both endpoints were met: IGA 0/1 response was 43.1% with lebrikizumab versus 12.7% with placebo (p<0.000001), and EASI-75 response was 58.8% versus 16.2% (p<0.000001).
Next expected readout: April 2027 · NCT06526182 (registry estimate)
Reported efficacy
Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16; Percentage of Participants Achieving Eczema Area And Severity Index (EASI-75) (≥75% Reduction in EASI Score) From Baseline to Week 16: Percentage of Participants With an Investigator Global Assessment (IGA) Score of 0 or 1 and a Reduction ≥2 Points From Baseline to Week 16 (Baseline to Week 16): Lebrikizumab Q2W 33.2% (95% CI 27.5 to 38.9) vs Placebo 10.8% (95% CI 5.7 to 15.9) (met)
Result source: NCT04178967
REGN20423
Developed by Regeneron Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2028 · NCT07527923 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | lebrikizumab | REGN20423 |
|---|---|---|
| EASI-75 | 51.2% vs 13.4%+37.8 vs placeboNCT0476031410 other results
| —Not reported |
| IGA 0/1 with 2-point improvement | 33.4% vs 6.1%+27.3 vs placeboNCT047603145 other results
| —Not reported |
| EASI-90 | 34.3% vs 9.8%+24.5 vs placeboNCT0476031411 other results
| —Not reported |
| EASI, % change | -64.2% vs -25.3%−39 vs placeboNCT047603147 other results
| —Not reported |
EASI-75
- lebrikizumab
- 51.2% vs 13.4%+37.8 vs placeboNCT04760314
10 other results
- 58.8% vs 16.2% NCT04146363
- 52.1% vs 18.1% NCT04178967
- 47.2% vs 13.4% NCT04760314
- 69.5% vs 42.2% NCT04250337
- 58% vs 32.7% NCT04626297
- 84.7% vs 72% NCT04178967
- 77.4% vs 72% NCT04178967
- 60.6% vs 24.3% NCT03443024
- 56.1% vs 24.3% NCT03443024
- 43.3% vs 24.3% NCT03443024
- REGN20423
- —Not reported
IGA 0/1 with 2-point improvement
- lebrikizumab
- 33.4% vs 6.1%+27.3 vs placeboNCT04760314
5 other results
- 29.1% vs 6.1% NCT04760314
- 41.2% vs 22.1% NCT04250337
- 44.6% vs 15.3% NCT03443024
- 33.7% vs 15.3% NCT03443024
- 26.6% vs 15.3% NCT03443024
- REGN20423
- —Not reported
EASI-90
- lebrikizumab
- 34.3% vs 9.8%+24.5 vs placeboNCT04760314
11 other results
- 39.2% vs 18.9% NCT04626297
- 38.3% vs 9% NCT04146363
- 30.7% vs 9.5% NCT04178967
- 41.2% vs 21.7% NCT04250337
- 12.4% vs 1.6% NCT04146363
- 6.3% vs 1.5% NCT04178967
- 28.4% vs 9.8% NCT04760314
- 10.7% vs 7.2% NCT04250337
- 44% vs 11.4% NCT03443024
- 36.1% vs 11.4% NCT03443024
- 26.1% vs 11.4% NCT03443024
- REGN20423
- —Not reported
EASI, % change
- lebrikizumab
- -64.2% vs -25.3%−39 vs placeboNCT04760314
7 other results
- -64.3% vs -26.0% NCT04146363
- -61.5% vs -28.0% NCT04178967
- -59.7% vs -25.3% NCT04760314
- -76.8% vs -53.1% NCT04250337
- -72.1% vs -41.1% NCT03443024
- -69.2% vs -41.1% NCT03443024
- -62.3% vs -41.1% NCT03443024
- REGN20423
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
REGN20423: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. lebrikizumab: 4 of 4 rows · REGN20423: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | lebrikizumab |
|---|---|
| Dropout rate | —250mg Q2Wa NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 54 more results—Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250mg Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 7.2% NCT04250337 · Phase 3 · combination 6.5% NCT05990725 · Phase 3 · registry result, not featured evidence —Q4W NCT04392154 · Phase 3 · registry result, not featured evidence —Q8W NCT04392154 · Phase 3 · registry result, not featured evidence 33.3%Q2W NCT04392154 · Phase 3 · registry result, not featured evidence 27%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence 14.4%250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 31.4%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then Q4W NCT05369403 · Phase 3 · registry result, not featured evidence 0%Lebrikizumab Pen NCT06444165 · Phase 3 · registry result, not featured evidence —Lebrikuzimab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 3.6%Double-blind Induction Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence · combination —Open-label Maintenance Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 2.4%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 1.2%250mg Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —250 Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 11%250 mg NCT04626297 · Phase 3 · registry result, not featured evidence 16.5%250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT03443024 · Phase 2 · registry result, not featured evidence 38.8%250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence —125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —250mg Q2Wa NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 54 more results—Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250mg Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Escape Arm Week 24 to 48 - Mainten NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2% NCT04250337 · Phase 3 · combination 1.9% NCT05990725 · Phase 3 · registry result, not featured evidence —Q4W NCT04392154 · Phase 3 · registry result, not featured evidence —Q8W NCT04392154 · Phase 3 · registry result, not featured evidence 4.5%Q2W NCT04392154 · Phase 3 · registry result, not featured evidence 2.1%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 5.8%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —Lebrikizumab Pen NCT06444165 · Phase 3 · registry result, not featured evidence —Lebrikuzimab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 0.9%Double-blind Induction Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence · combination —Open-label Maintenance Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 1.6%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0%250mg Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —250 Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence —Q2W NCT04760314 · Phase 3 · registry result, not featured evidence —Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 2.4%250 mg NCT04626297 · Phase 3 · registry result, not featured evidence 2.4%250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg NCT04250350 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT03443024 · Phase 2 · registry result, not featured evidence 5%250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence —125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 2.1%250mg Q2Wa NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 54 more results3.8%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Escape Arm Week 24 to 48 - Mainten NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.2%Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.7%250mg Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.9%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Escape Arm Week 24 to 48 - Mainten NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3.4%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 22.2%Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q2W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —250 Q4W NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.3% NCT04250337 · Phase 3 · combination 2.7% NCT05990725 · Phase 3 · registry result, not featured evidence 0%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence 0%Q8W NCT04392154 · Phase 3 · registry result, not featured evidence 4.4%Q2W NCT04392154 · Phase 3 · registry result, not featured evidence 3.5%Q4W NCT04392154 · Phase 3 · registry result, not featured evidence 0%250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 0%250 mg Q2W NCT05372419 · Phase 3 · registry result, not featured evidence 1.8%250 mg Q2W then 250 mg Q4W NCT05372419 · Phase 3 · registry result, not featured evidence 1.2%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence —250 mg Q2W then 250 mg Q4W NCT05369403 · Phase 3 · registry result, not featured evidence 0%250 mg Q2W NCT05369403 · Phase 3 · registry result, not featured evidence 2.4%250 mg Q2W then Q4W NCT05369403 · Phase 3 · registry result, not featured evidence —Lebrikizumab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 0%Lebrikuzimab Pen NCT06444165 · Phase 3 · registry result, not featured evidence 1.4%Double-blind Induction Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence · combination 5.7%Open-label Maintenance Period: Leb NCT05149313 · Phase 3 · registry result, not featured evidence 1.4%250 mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 1.8%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 4.8%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0.8%250mg Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0%250mg Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 12.5%250 Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 0%Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 3.1%Q2W NCT04760314 · Phase 3 · registry result, not featured evidence 2.6%Q4W NCT04760314 · Phase 3 · registry result, not featured evidence 0.8%250 mg NCT04626297 · Phase 3 · registry result, not featured evidence —250 mg NCT04250350 · Phase 3 · registry result, not featured evidence 2.4%250 mg NCT04250350 · Phase 3 · registry result, not featured evidence 2.7%250 mg Q2W NCT03443024 · Phase 2 · registry result, not featured evidence 0%250 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence 2.7%125 mg Q4W NCT03443024 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 250mg Q2Wa conjunctivitis 7.4% (placebo 2.8%) dermatitis atopic 5.7% (placebo 21.3%) nasopharyngitis 3.9% (placebo 2.8%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 43 more resultsQ2W conjunctivitis 4.7% (placebo 2.8%) conjunctivitis allergic 4.7% (placebo 0.7%) asthma 3.8% (placebo 0.7%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W conjunctivitis 9.4% (placebo 2.8%) conjunctivitis allergic 6.3% (placebo 0.7%) dermatitis atopic 6.3% (placebo 21.3%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 bursitis 5.6% (placebo 0.7%) carpal tunnel syndrome 5.6% (placebo 0%) conjunctivitis 5.6% (placebo 2.8%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W covid-19 3.2% (placebo 2.1%) dermatitis atopic 3.2% (placebo 21.3%) hypertension 3.2% (placebo 0.7%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W covid-19 12.7% (placebo 2.1%) nasopharyngitis 9.5% (placebo 2.8%) dermatitis atopic 6.3% (placebo 21.3%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W abscess limb 10% (placebo 0%) chest wall abscess 10% (placebo 0%) nasopharyngitis 10% (placebo 2.8%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W covid-19 10% (placebo 2.1%) nasopharyngitis 10% (placebo 2.8%) oral herpes 10% (placebo 3.5%) NCT04146363 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 250mg Q2W dermatitis atopic 9.2% (placebo 25.5%) conjunctivitis 7.1% (placebo 2%) headache 5.1% (placebo 5.4%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W nasopharyngitis 8% (placebo 2%) dermatitis atopic 4.8% (placebo 25.5%) conjunctivitis 2.4% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W conjunctivitis allergic 11.1% (placebo 1.3%) covid-19 5.6% (placebo 1.3%) nasopharyngitis 5.6% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 asthma 18.2% (placebo 0%) dermatitis atopic 18.2% (placebo 25.5%) herpes dermatitis 9.1% (placebo 1.3%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W vaccination complication 6.8% (placebo 0%) dermatitis atopic 5.1% (placebo 25.5%) folliculitis 5.1% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W conjunctivitis 8.5% (placebo 2%) conjunctivitis allergic 6.8% (placebo 1.3%) covid-19 5.1% (placebo 1.3%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q2W hypercholesterolaemia 18.2% (placebo 0.7%) nasopharyngitis 18.2% (placebo 2%) acne 9.1% (placebo 2%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 Q4W arthralgia 11.1% (placebo 0.7%) blood lactate dehydrogenase increased 11.1% (placebo 0%) blood uric acid increased 11.1% (placebo 0%) NCT04178967 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 conjunctivitis 4.6% (placebo 0%) headache 4.6% (placebo 1.3%) hypertension 2.6% (placebo 1.3%) NCT04250337 · Phase 3 · combination nasopharyngitis 25.4% conjunctivitis 17.7% dermatitis atopic 11.5% NCT05990725 · Phase 3 · registry result, not featured evidence Q4W nasopharyngitis 3.8% acne 1.9% attention deficit hyperactivity disorder 1.9% NCT04392154 · Phase 3 · registry result, not featured evidence Q8W accessory navicular syndrome 2% alanine aminotransferase increased 2% arthralgia 2% NCT04392154 · Phase 3 · registry result, not featured evidence Q2W covid-19 15.7% nasopharyngitis 11.4% dermatitis atopic 6.9% NCT04392154 · Phase 3 · registry result, not featured evidence Q4W covid-19 18.4% nasopharyngitis 9.2% dermatitis atopic 6.4% NCT04392154 · Phase 3 · registry result, not featured evidence 250 mg Q2W back pain 2.2% nasopharyngitis 2.2% acanthosis nigricans 1.1% NCT05372419 · Phase 3 · registry result, not featured evidence 250 mg Q2W back pain 4.8% blood creatine phosphokinase increased 4.8% dermatitis atopic 4.8% NCT05372419 · Phase 3 · registry result, not featured evidence 250 mg Q2W then 250 mg Q4W conjunctivitis 3.6% nasopharyngitis 3.6% acne 1.8% NCT05372419 · Phase 3 · registry result, not featured evidence 250 mg Q2W dermatitis atopic 5.8% upper respiratory tract infection 4.7% injection site pain 3.5% NCT05369403 · Phase 3 · registry result, not featured evidence 250 mg Q2W concussion 5.6% conjunctivitis 5.6% covid-19 5.6% NCT05369403 · Phase 3 · registry result, not featured evidence 250 mg Q2W then Q4W joint swelling 4.9% viral upper respiratory tract infection 4.9% acne 2.4% NCT05369403 · Phase 3 · registry result, not featured evidence nasopharyngitis 12.7% (placebo 12.6%) conjunctivitis 11.4% (placebo 1.8%) conjunctivitis allergic 8.2% (placebo 2.7%) NCT05149313 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 24.5% (placebo 12.6%) conjunctivitis 11.8% (placebo 1.8%) conjunctivitis allergic 8.5% (placebo 2.7%) NCT05149313 · Phase 3 · registry result, not featured evidence 250 mg Q2W conjunctivitis allergic 18.3% (placebo 4.9%) covid-19 18.3% (placebo 2.4%) pyrexia 18.3% (placebo 15.9%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q2W covid-19 21.8% (placebo 2.4%) nasopharyngitis 12.7% (placebo 2.4%) acne 10.9% (placebo 6.1%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q2W covid-19 19% (placebo 2.4%) herpes simplex 19% (placebo 2.4%) nasopharyngitis 14.3% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q2W pyrexia 20.3% (placebo 15.9%) conjunctivitis allergic 17.1% (placebo 4.9%) conjunctivitis 9.8% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence 250mg Q4W pyrexia 18.5% (placebo 15.9%) conjunctivitis allergic 12.3% (placebo 4.9%) conjunctivitis 6.2% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence 250 Q2W covid-19 25% (placebo 2.4%) abdominal pain 12.5% (placebo 1.2%) acne 12.5% (placebo 6.1%) NCT04760314 · Phase 3 · registry result, not featured evidence Q4W covid-19 21.2% (placebo 2.4%) acne 18.2% (placebo 6.1%) headache 18.2% (placebo 11%) NCT04760314 · Phase 3 · registry result, not featured evidence Q2W pyrexia 34.4% (placebo 15.9%) conjunctivitis allergic 12.5% (placebo 4.9%) covid-19 12.5% (placebo 2.4%) NCT04760314 · Phase 3 · registry result, not featured evidence Q4W covid-19 18.4% (placebo 2.4%) pyrexia 18.4% (placebo 15.9%) conjunctivitis allergic 13.2% (placebo 4.9%) NCT04760314 · Phase 3 · registry result, not featured evidence 250 mg covid-19 5.5% (placebo 3.9%) dermatitis atopic 4.7% (placebo 6.3%) headache 3.1% (placebo 0.8%) NCT04626297 · Phase 3 · registry result, not featured evidence 250 mg dermatitis atopic 12.6% nasopharyngitis 9.7% covid-19 9.2% NCT04250350 · Phase 3 · registry result, not featured evidence 250 mg Q2W nasopharyngitis 12% (placebo 3.8%) headache 5.3% (placebo 5.8%) injection site pain 5.3% (placebo 1.9%) NCT03443024 · Phase 2 · registry result, not featured evidence 250 mg Q4W upper respiratory tract infection 11.3% (placebo 5.8%) fatigue 5% (placebo 0%) diarrhoea 3.8% (placebo 0%) NCT03443024 · Phase 2 · registry result, not featured evidence 125 mg Q4W upper respiratory tract infection 8.2% (placebo 5.8%) nasopharyngitis 5.5% (placebo 3.8%) bacterial vaginosis 4.3% (placebo 0%) NCT03443024 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 35 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
lebrikizumab
show 10 more results
show 10 more results
show 11 more results
show 5 more results
show 15 more results
show 7 more results
show 5 more results
show 2 more results
show 3 more results
show 5 more results
show 3 more results
+ 88 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lebrikizumab's landscape · REGN20423's landscape